Harvard Bioscience, Inc. (HBIO): Price and Financial Metrics
Harvard Bioscience, Inc. (HBIO)
Today's Latest Price: $3.21 USD
Updated Aug 3 8:00pm
Add HBIO to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 58 in Medical - Diagnostics/Research
See all "A" rated Strong Buy stocks
HBIO Stock Summary
- With a year-over-year growth in debt of -12.48%, Harvard Bioscience Inc's debt growth rate surpasses merely 18.77% of about US stocks.
- Over the past twelve months, HBIO has reported earnings growth of -403.17%, putting it ahead of only 4.59% of US stocks in our set.
- The volatility of Harvard Bioscience Inc's share price is greater than that of merely 22.17% US stocks with at least 200 days of trading history.
- Stocks with similar financial metrics, market capitalization, and price volatility to Harvard Bioscience Inc are BDC, VAPO, STIM, LNDC, and CAMP.
- HBIO's SEC filings can be seen here. And to visit Harvard Bioscience Inc's official web site, go to www.harvardbioscience.com.
HBIO Stock Price Chart Technical Analysis Charts
HBIO Price/Volume Stats
| Current price | $3.21 | 52-week high | $3.77 |
| Prev. close | $3.11 | 52-week low | $1.39 |
| Day low | $3.04 | Volume | 125,000 |
| Day high | $3.21 | Avg. volume | 233,295 |
| 50-day MA | $3.07 | Dividend yield | N/A |
| 200-day MA | $2.82 | Market Cap | 123.20M |
Harvard Bioscience, Inc. (HBIO) Company Bio
Harvard Bioscience, Inc. develops, manufactures, and markets scientific instruments, systems, and lab consumables used in life science research. The company was founded in 1901 and is based in Holliston, Massachusetts.
HBIO Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $3.21 | $2.52 | -19% |
Below please find a table outlining a discounted cash flow forecast for HBIO, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Harvard Bioscience Inc ranked in the 43th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. The most interesting components of our discounted cash flow analysis for Harvard Bioscience Inc ended up being:
- The company's balance sheet shows it gets 67% of its capital from equity, and 33% of its capital from debt. Notably, its equity weight is greater than only 23.81% of US equities in the Healthcare sector yielding a positive free cash flow.
- Harvard Bioscience Inc's interest coverage rate -- a measure of gross earnings relative to interest payments -- comes in at -0.54. This coverage rate is greater than that of merely 22.02% of stocks we're observing for the purpose of forecasting via discounted cash flows.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -21% |
| 1% | -20% |
| 2% | -19% |
| 3% | -18% |
| 4% | -17% |
| 5% | -17% |
Want more companies with a valuation profile/forecast similar to that of Harvard Bioscience Inc? See ICLR, DGX, GILD, CRL, and CAH.
Loading social stream, please wait...